Skip to Content

Posts tagged with "Diabetes and Obesity"

  • "Me Too" Drugs

    Gritting Our Teeth

    I’ll tell you a company that’s been watching what’s happened to Merck and thinking hard about it: Sanofi. Well, OK, everyone in the industry has been looking at Merck’s situation and shuddering, but I suspect the people at Sanofi(-Aventis) are especially jumpy. Why? Rimonabant. Rimonabant, which will come to the market next… Read More
  • Diabetes and Obesity

    Symlin, At Last

    I wanted to take a moment to congratulate Amylin on the FDA approval of their diabetes therapy Symlin. I’ve known a couple of people out there over the years. Actually, a lot of people have had a chance to know someone at Amylin, because the company has had more than one near-death experience, during which… Read More
  • Diabetes and Obesity

    Worries about Rimonabant?

    Continuing on the theme of unexpected toxicity landmines, I wanted to take a look at a highly anticipated obesity drug from Sanofi. Rimonabant is a small molecule antagonist of the CB-1 receptor, and it’s been getting a lot of press – both for its impressive efficacy and for its mechanism of action. The “CB” in… Read More
  • Cancer

    Bungee Jumping with PPAR Drugs

    The PPAR family (known in the US as alpha, gamma, and delta, for obscure historical reasons) is one of those biological jungles that keep us all employed. They’re nuclear receptors, and thus they’re involved in up- and down-regulation of hundreds of genes. Like most of the other nuclear receptors, they do that by responding to… Read More
  • Diabetes and Obesity

    Why Own the Car, When You Can Own the Road?

    I’ve written before about method-of-treatment patents, and now the subject makes today’s front page of the Wall Street Journal. They’ve picked a pure example of the breed. Hans-Ulrich Demuth at the University of Halle in Germany filed for a patent in 1996 on the use of inhibitors of dipeptidyl peptidase IV in the treatment of… Read More
  • Business and Markets

    Ah, Marketing

    The Advertising column in today’s Wall St. Journal has an interesting note on some recent Merck ads for their COX-2 inhibitor, Vioxx. What they’ve done is break their TV ads up into pieces. Why would you do that? Well, the FDA rules are that if you mention a drug and what it’s good for in… Read More
  • Diabetes and Obesity

    Of All Sad Words. . .

    If you want a good example of how something that seems completely sensible can backfire in drug development, look no further than the story of leptin. I remember when this peptide hormone was discovered in rodents in 1995: the news really made a splash among groups working on obesity and metabolic therapies. If you raised… Read More
  • Diabetes and Obesity

    Fighting City Hall

    A point I made in yesterday’s post is worth expanding on – my scepticism about the advent of the Magic Pizza Pill. It’s not just hard to develop an obesity drug. It’s hard to fight almost any of the biological pathways, even when they’re doing harm. Evolution has whittled some of them down to lean… Read More
  • Diabetes and Obesity

    A Treadmill Pill?

    There was quite a wave of publicity about a possible “exercise pill” recently. The folks over at Godless Capitalist asked me to take a crack at explaining what all the noise is about. As you might imagine, though, the original research that set this off is a bit less sensational: “Regulation of Mitochondrial Biogenesis in… Read More
  • Diabetes and Obesity

    Enzymes, Right and Wrong

    >A post of mine from February 26 mentioned in passing the side effects of the anti-HIV protease inhibitor drugs. There’s nothing inherent in their mechanism that should cause lipid profile changes and insulin resistance, so the hunt has been on for what other target is responsible. Now a team at Washington University in St. Louis… Read More